An open-label, flexible-dose trial of the safety and efficacy of Geodon [ziprasidone] in non-rapid-cycling bipolar II patients with major depression

Trial Profile

An open-label, flexible-dose trial of the safety and efficacy of Geodon [ziprasidone] in non-rapid-cycling bipolar II patients with major depression

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2013

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 03 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top